COMMENTARY: BRCA1/2 Mutations, Vulnerability to Breast/Ovarian Cancer, and Current and Future Treatment Modalities

• Ananda M. Chakrabarty

  Department of Microbiology & Immunology, University of Illinois College of Medicine, 835 S. Wolcott Avenue, Chicago, IL 60612, USA

Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002; 21: 8981-93. http://dx.doi.org/10.1038/sj.onc.1206176

Kalb R, Mallery DL, Larkin C, Huang JTJ, Hiom, K. BRCA1 is a histone-H2A-specific ubiquitin ligase. Cell Reports 2014; 8: 999-1005. http://dx.doi.org/10.1016/j.celrep.2014.07.025

Fialho AM, Chakrabarty, AM. Promiscuous anticancer drugs from pathogenic bacteria: rational versus intelligent drug design. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. Fialho, AM, Chakrabarty, AM, Eds. New York: Wiley 2010. http://dx.doi.org/10.1002/9780470626528

Chakrabarty, AM, Bernerdes, N, Fialho, AM. Bacterial proteins and peptides in cancer therapy: today and tomorrow. Bioengineered 2014; 5: 234-42. http://dx.doi.org/10.4161/bioe.29266

Warso, MA, Richards, JM, Mehta, D, Christov, K, Schaeffer, C. et al. A first-in-class first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Brit J Cancer 2013; 108: 1061-70. http://dx.doi.org/10.1038/bjc.2013.74

• PDF